Compounds |
|
 |
|
|
|
AA018:(3S,2S)-2,3-Diaminobutyric acid 2Hydrochloride,121054-30-6,98%
|
|
 |
|
]: |
|
[Product Name |
]: |
(3S,2S)-2,3-Diaminobutyric acid 2Hydrochloride |
[CAS |
]: |
121054-30-6 |
[Molecular formula |
]: |
|
[Quality |
]: |
98% |
[Specturm |
]: |
H-NMR;HPLC spectrum |
[Quantity |
]: |
10g;100g;1000g |
| |
|
| |
[Certificate of Analysis |
]: |
|
| |
[MSDS |
]: |
|
| |
[Price |
]: |
|
| |
|
]: |
|
[1]Stock compound will be delivered within 3 days; [2]The H-NMR and HPLC specturm (or other necessary test specturms) of custom synthesis compound will be sent for your approval proir to shippment.[3]Controlled compound and Patented compound are not available.[4] You can also send an inquiry and order via online order or to info@lanospharma.com |
During the last 9 years,we have established a good cooperation with the famous Research Institutes,Chemical and pharmaceutical companies all over the world. |
2008- |
Applichem |
Germany |
2009- |
Brookwoodpharma |
USA |
2010- |
Formosalab |
Taiwan |
2011- |
Sanofi-Aventis |
Czech republic |
2012- |
Abcam |
UK |
2012- |
Chemimpex |
USA |
2013- |
Stanford University |
USA |
2013- |
|
Ireland |
2014- |
Neuland Pharma Research |
India |
2014- |
LeeChem Co.,Ltd |
Korea |
2015- |
Chemos |
Germany |
2015- |
Novartis |
China |
2016- |
Henkel Corporation |
USA |
| |
Contact us for more information
|
|
PD1 |
Products protected by valid patents are not offered for sale in jurisdictions where the sale of such products constitutes a patent infringement. The current list only reflects the products and technologies that are available, under development: note that some products may be developed or produced for internal and experimental uses with no commercal aim. |
PD2 |
Sales of products are limited to those allowed by Chapter VII PLPRC 63, the above includes Research and development quantities. |
PD3 |
R&D use in accordance with (1) 35 USC 271(e)+A13(1) in the U.S.; (2) Section 69.1 of Japanese Patent Law in Japan; (3) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (4) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (5) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (6) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (7) such similar laws and rules as may apply in various other countries.
|
PD4 |
the buyer assumes responsibility of all patent considerations in the use of (3S,2S)-2,3-Diaminobutyric acid 2Hydrochloride,121054-30-6.
|
|
